Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ferris

Showing results (451-460 of 460) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 460 results.
Journal of Medicinal Chemistry|June 1, 2001
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1J H Chan, J S Hong, R N Hunter, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 yearsDarron R Brown, Susanne K Kjaer, Kristján Sigurdsson, et al.
Journal of the National Cancer Institute|February 9, 2010
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young womenNubia Muñoz, Susanne K Kjaer, Kristján Sigurdsson, et al.
Nature|January 24, 2020
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivoChristopher C Nixon, Maud Mavigner, Gavin C Sampey, et al.
Pageof 46

Showing results (451-460 of 460) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 460 results.
Journal of Medicinal Chemistry|June 1, 2001
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1J H Chan, J S Hong, R N Hunter, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 yearsDarron R Brown, Susanne K Kjaer, Kristján Sigurdsson, et al.
Journal of the National Cancer Institute|February 9, 2010
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young womenNubia Muñoz, Susanne K Kjaer, Kristján Sigurdsson, et al.
Nature|January 24, 2020
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivoChristopher C Nixon, Maud Mavigner, Gavin C Sampey, et al.
Pageof 46